2021
Reperfusion therapies and in-hospital outcomes for ST-elevation myocardial infarction in Europe: the ACVC-EAPCI EORP STEMI Registry of the European Society of Cardiology
ZEYMERT, U., P. LUDMAN, N. DANCHIN, Petr KALA, C. LAROCHE et. al.Základní údaje
Originální název
Reperfusion therapies and in-hospital outcomes for ST-elevation myocardial infarction in Europe: the ACVC-EAPCI EORP STEMI Registry of the European Society of Cardiology
Autoři
ZEYMERT, U. (garant), P. LUDMAN, N. DANCHIN, Petr KALA (203 Česká republika, domácí), C. LAROCHE, M. SADEGHI, R. CAPORALE, S. M. SHAHEEN, J. LEGUTKO, Z. IAKOBSISHVILI, K. F. ALHABIB, Z. MOTOVSKA, M. STUDENCAN, J. MIMOSO, D. BECKER, D. ALEXOPOULOS, Z. KERESESELIDZE, S. STOJKOVIC, P. ZELVEIAN, A. GODA, E. MIRRAKHIMOV, G. BAJRAKTARI, H. AL-FARHAN, P. SERPYTIS, B. RAUNGAARD, T. MARANDI, A. M. MOORE, M. QUINN, P. P. KARJALAINEN, G. TATU-CHITOLU, C. P. GALE, A. P. MAGGIONI a F. WEIDINGER
Vydání
European heart journal, Oxford, Oxford University Press, 2021, 0195-668X
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30201 Cardiac and Cardiovascular systems
Stát vydavatele
Velká Británie a Severní Irsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 35.855
Kód RIV
RIV/00216224:14110/21:00124152
Organizační jednotka
Lékařská fakulta
UT WoS
000738992000010
Klíčová slova anglicky
ST-elevation myocardial infarction; Primary percutaneous coronary intervention; Observational studies; Reperfusion therapy
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 17. 5. 2022 13:11, Mgr. Tereza Miškechová
Anotace
V originále
Aims The aim of this study was to determine the contemporary use of reperfusion therapy in the European Society of Cardiology (ESC) member and affiliated countries and adherence to ESC clinical practice guidelines in patients with ST-elevation myocardial infarction (STEMI). Methods and results Prospective cohort (EURObservational Research Programme STEMI Registry) of hospitalized STEMI patients with symptom onset <24h in 196 centres across 29 countries. A total of 11 462 patients were enrolled, for whom primary percutaneous coronary intervention (PCI) (total cohort frequency: 72.2%, country frequency range 0-100%), fibrinolysis (18.8%; 0-100%), and no reperfusion therapy (9.0%; 0-75%) were performed. Corresponding in-hospital mortality rates from any cause were 3.1%, 4.4%, and 14.1% and overall mortality was 4.4% (country range 2.55.9%). Achievement of quality indicators for reperfusion was reported for 92.7% (region range 84.8 97.5%) for the performance of reperfusion therapy of all patients with STEMI <12h and 54.4% (region range 37.1-70.1%) for timely reperfusion. Conclusions The use of reperfusion therapy for STEMI in the ESC member and affiliated countries was high. Primary PCI was the most frequently used treatment and associated total in-hospital mortality was below 5%. However, there was geographic variation in the use of primary PCI, which was associated with differences in in-hospital mortality. [GRAPHICS] .